Y., Akhtari, H., Nematizadeh, M., & Safarian, M
While some patients report improvements in energy and body composition, the evidence for direct weight loss is limited and far weaker than what exists for GLP-1 receptor agonists
First things first, let's get your supplies in order
The standard schedule begins at 0.3 mg weekly for four weeks, then escalates to 0.6 mg for four weeks, followed by 1.2 mg for four weeks, then 1.8 mg for four weeks, ultimately reaching the maintenance dose of 2.4 mg weekly
Several large studies using electronic health records and insurance claims data have tracked people using GLP-1 medications for five years or more
Beyond the initial approvals (FDA 2017, EMA 2018), real-world evidence confirms the clinical benefits of semaglutide, while ongoing post marketing has thus far revealed no unexpected safety signals